Anlotinib hydrochloride

Anlotinib hydrochloride (international nonproprietary name: catequentinib) [11] is a multi-kinase inhibitor already approved in China across non-small cell lung cancer, soft tissue sarcoma (STS), and small cell lung cancer. Chia Tai Tianqing (CTTQ) ran the Phase 3 ANCHOR trial (NCT04854668) of anlotinib plus CapeOX (capecitabine + oxaliplatin) versus bevacizumab plus CapeOX as first-line (1L) treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) [1]. The trial read out at ASCO 2025: progression-free survival (PFS) was 11.04 months in both arms, with comparable safety - anlotinib showed non-inferiority but not superiority versus bevacizumab on the primary endpoint [9]. The commercial implication is mixed. For CTTQ in China, this supports an NMPA filing for another major indication and gives them a domestically-developed oral alternative to imported bevacizumab biosimilars. For the broader question of whether multi-kinase inhibition beats anti-VEGF antibodies in 1L mCRC, the answer is 'no, not on PFS.' An oral pill versus an IV biologic with equivalent efficacy is a tolerability and convenience story, not a paradigm shift, and US/EU registration remains uncommitted.

Anlotinib received its first NMPA approval in May 2018 for third-line advanced non-small cell lung cancer based on the ALTER-0303 trial [2], then picked up Chinese approvals for soft tissue sarcoma and small cell lung cancer. A Phase II trial in radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC) met its primary endpoint with substantial PFS extension over placebo and supports the thyroid indication pathway [12]; medullary and anaplastic histologies were not the basis of approval and should not be conflated with RAIR-DTC. Anlotinib is NOT approved by the FDA or EMA, and CTTQ has not publicly committed to a US registration trial in colorectal cancer. The Phase 3 ANCHOR trial (NCT04854668) [1] enrolled 748 patients between May 2021 and August 2023 (planned 698, actual 748) and is now complete; primary results were presented at ASCO 2025 [9]. The patient population - RAS/BRAF wild-type mCRC - is currently dominated by FOLFOX or FOLFIRI (standard chemotherapy backbones combining leucovorin, fluorouracil, and either oxaliplatin or irinotecan) with bevacizumab or anti-EGFR antibodies (cetuximab, panitumumab). No breakthrough therapy, fast track, orphan, or RMAT designations apply - this is a Chinese asset running through Chinese regulators. CTTQ is also pushing anlotinib into checkpoint-inhibitor combinations: a Phase 3 of TQB2868 (anti-PD-L1) plus anlotinib in first-line (1L) metastatic pancreatic cancer (NCT07165951) [3] and a Phase 2 of nivolumab plus anlotinib in gastric and esophageal cancer (the OASIS trial) [4].

Anlotinib blocks several receptor tyrosine kinases, proteins on cell surfaces that act as docking stations for growth signals [5]. The main targets are VEGFR1/2/3 (blocks signals that tell tumors to grow new blood vessels and feed themselves), FGFR1-4 (another growth-signal receptor that some tumors hijack), PDGFRα/β (signals the stromal cells supporting tumors), and c-KIT (the stem cell factor receptor implicated in sarcomas and gastrointestinal stromal tumors). The dominant biological lever in colorectal cancer is the VEGFR axis: tumors need to recruit new blood vessels to grow past a few millimeters, and shutting down VEGFR2 starves them. This mechanism is genetically and clinically validated - bevacizumab (anti-VEGF antibody), regorafenib (oral multi-kinase) [6], and fruquintinib (oral VEGFR1/2/3 inhibitor) [7] all carry CRC approvals built on it. Where anlotinib differs from fruquintinib or bevacizumab is the broader receptor coverage. Whether hitting FGFR and PDGFR on top of VEGFR translates into better survival in CRC, or just more toxicity without added benefit, was the actual scientific question of NCT04854668. The ANCHOR readout answers it: broader receptor coverage produced equivalent - not superior - PFS versus pure anti-VEGF on a chemo backbone [9]. The mechanism is well-validated for CRC; the multi-target version is not demonstrably *better* than the standard anti-VEGF.

NCT04854668 (ANCHOR) was an open-label, randomized, multicenter Phase 3 trial of anlotinib plus CapeOX versus bevacizumab plus CapeOX as first-line therapy in RAS/BRAF wild-type metastatic colorectal cancer [1]. Primary endpoint: progression-free survival assessed by independent review committee (IRC). Planned enrollment was 698 patients randomized 1:1; actual enrollment closed at 748 between May 2021 and August 2023 [9]. The CapeOX backbone (oral capecitabine + intravenous oxaliplatin) is the China-preferred 1L regimen and matters for interpretation: a trial using FOLFOX or FOLFIRI as the backbone would have produced a more globally portable comparison but a less locally relevant one. The 'RAS/BRAF wild-type' selection identifies the patient subgroup where anti-EGFR antibodies like cetuximab and panitumumab also work, and is the population where bevacizumab plus a chemo backbone is the established benchmark. Open-label design is acceptable for PFS as primary but introduces bias on response-based secondary endpoints. Because the comparator is bevacizumab plus the same chemotherapy backbone - not chemo alone - this trial was structured as a true head-to-head against the antiangiogenic standard, which is the right design to answer the relevant commercial question. The reported readout is non-inferior PFS (11.04 months both arms) with comparable safety; overall survival, response rate, and the full safety breakdown will determine the regulatory and commercial weight of the result [9].

Our model gives this drug a 21% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 3 drugs in this area - about 48% - then adjusts based on ten facts about the trial and the sponsor. The biggest drag on the number is the sponsor's thin approval record and weak earlier-phase results; the open-label trial design provides a partial offset. Most other factors are close to average for this stage and leave the estimate roughly where the base rate set it.

Efficacy risk is now retrospective. Multiple antiangiogenic challengers have tried to displace bevacizumab in first-line mCRC and failed to show clear OS benefit - ramucirumab plus FOLFIRI did not beat bevacizumab plus FOLFIRI in 1L, and aflibercept's 1L data is similarly underwhelming. The ANCHOR result fits that pattern: anlotinib is more potent and hits more receptors, but broader receptor coverage did not translate to better PFS [9]. Whether OS data (when mature) shifts the interpretation is the remaining clinical question. Safety risk is mechanism-based and predictable: multi-kinase inhibitors cause hypertension, hand-foot skin reaction, proteinuria, hypothyroidism, fatigue, and uncommon-but-serious gastrointestinal perforation or bleeding. Regorafenib's tolerability is rough enough that real-world dose reductions are routine; the ALTER-0303 advanced-NSCLC safety data show anlotinib has a manageable but non-trivial toxicity profile [2], and ANCHOR reported comparable safety to bevacizumab plus chemo [9] - a meaningful finding given the added oral multi-kinase agent. Execution risk: open-label and primarily Chinese, which is fine for an NMPA filing but creates a gap for any FDA/EMA discussion since Western regulators will want a multi-regional study. Commercial risk: even with positive data, China's National Reimbursement Drug List (NRDL) - which sets reimbursed pricing for approved drugs and requires aggressive price concessions for inclusion - will compress margins, and global commercialization needs either a partner or a Western trial that CTTQ has not committed to running. NMPA approval in China is plausible on the readout; meaningful global revenue is a separate, much harder problem requiring infrastructure CTTQ does not yet have outside Asia.

Watch as a China-pharma story with limited Western near-term implications. CTTQ is the dominant Chinese oncology pharma that built anlotinib into a multi-indication franchise on the back of ALTER-0303 [2], and they execute Phase 3s through NMPA reliably. The ANCHOR readout (non-inferior PFS vs bevacizumab + CapeOX) is commercially useful for CTTQ in China - it positions an oral domestic agent against imported biologic bevacizumab biosimilars and supports a 1L mCRC label expansion - but it is roughly meaningless globally. There was no superiority signal that would force a re-rating of multi-kinase versus pure anti-VEGF in CRC. Watch for: (1) overall survival update from ANCHOR (timing TBD), (2) full safety breakdown when the manuscript is published, (3) NMPA submission and NRDL negotiation outcome. For US-listed investors, this asset remains a barometer for how aggressively Chinese pharma is closing the antiangiogenic gap with Western standards rather than a near-term Western opportunity. The more differentiated CTTQ pipeline stories right now are the anlotinib-plus-checkpoint-inhibitor combinations - TQB2868 in first-line pancreatic cancer (NCT07165951) [3] and the OASIS gastric/esophageal trial [4] - which test theses more interesting than 'add another VEGFR drug to chemo in CRC'.